Back to Search Start Over

Characterizing SOD1 mutations in Spain: The impact of genotype, age and sex in the natural history of the disease.

Authors :
Vázquez‐Costa, Juan F.
Borrego‐Hernández, Daniel
Paradas, Carmen
Gómez‐Caravaca, María Teresa
Rojas‐Garcia, Ricardo
Varona, Luis
Povedano, Mónica
García‐Sobrino, Tania
Jericó Pascual, Ivonne
Gutiérrez, Antonio
Riancho, Javier
Turon‐Sans, Janina
Assialioui, Abdelilah
Pérez‐Tur, Jordi
Sevilla, Teresa
Esteban Pérez, Jesús
García‐Redondo, Alberto
López, Alberto Andrés
Calabria, M. Dolores
Díaz‐Marín, Carmen
Source :
European Journal of Neurology; Apr2023, Vol. 30 Issue 4, p861-871, 11p
Publication Year :
2023

Abstract

Background and purpose: The aim of this study was to describe the frequency and distribution of SOD1 mutations in Spain, and to explore factors contributing to their phenotype and prognosis. Methods: Seventeen centres shared data on amyotrophic lateral sclerosis (ALS) patients carrying pathogenic or likely pathogenic SOD1 variants. Multivariable models were used to explore prognostic modifiers. Results: In 144 patients (from 88 families), 29 mutations (26 missense, 2 deletion/insertion and 1 frameshift) were found in all five exons of SOD1, including seven novel mutations. A total of 2.6% of ALS patients (including 17.7% familial and 1.3% sporadic) were estimated to carry SOD1 mutations. The frequency of this mutation varied considerably among regions, due to founder events. The most frequent mutation was p.Gly38Arg (n = 58), followed by p.Glu22Gly (n = 11), p.Asn140His (n = 10), and the novel p.Leu120Val (n = 10). Most mutations were characterized by a protracted course, and some of them by atypical phenotypes. Older age of onset was independently associated with faster disease progression (exp[Estimate] = 1.03 [0.01, 0.05], p = 0.001) and poorer survival (hazard ratio 1.05 [1.01, 1.08], p = 0.007), regardless of the underlying mutation. Female sex was independently associated with faster disease progression (exp[Estimate] = 2.1 [1.23, 3.65], p = 0.012) in patients carrying the p.Gly38Arg mutation, resulting in shorter survival compared with male carriers (236 vs. 301 months). Conclusions: These data may help to evaluate the efficacy of SOD1 targeted treatments, and to expand the number of patients that might benefit from these treatments. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
13515101
Volume :
30
Issue :
4
Database :
Complementary Index
Journal :
European Journal of Neurology
Publication Type :
Academic Journal
Accession number :
162243121
Full Text :
https://doi.org/10.1111/ene.15661